ClinicalTrials.gg
Not yet recruitingNCT07518589Updated Apr 8, 2026

Phase 1 Study of Ascending Doses of CMS-D008 in Healthy and Overweight/Obese Adults

A Phase 1 interventional study of CMS-D008 and Placebo in Evaluate the Safety and Tolerability and Healthy and Overweight or Obese Participants, sponsored by Shenzhen Kangzhe Biotechnology Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by Shenzhen Kangzhe Biotechnology Co., Ltd. · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study is a first-in-human clinical trial of CMS-D008 conducted in Chinese healthy and overweight or obese adult participants, consisting of three parts: Part-1 Single Ascending Dose (SAD) study (hereinafter referred to as Part-1 SAD study), Part-2 Multiple Ascending Dose (MAD) study (hereinafter referred to as Part-2 MAD study), and Part-3 expansion study. The study aims to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) characteristics, and immunogenicity of single and multiple subcutaneous injections of CMS-D008 injection in Chinese healthy and overweight or obese adult participants.

02

Conditions studied

  • Evaluate the Safety and Tolerability
  • Healthy and Overweight or Obese Participants

Browse trials for

Keywords

  • Phase 1 clinical study
  • safety
  • fat loss
03

In context

Overweight

3,599 studies on the registry are indexed under Overweight; 852 are open to participants now.

This study's planned enrollment of 110 is above the median of 78 across 3,120 interventional studies indexed under Overweight.

Browse Overweight studies →

Lead sponsor

Shenzhen Kangzhe Biotechnology Co., Ltd. is the lead sponsor of 4 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily participate in this study, sign the form, be able to understand and comply with all requirements and restrictions of the study, and complete the study in accordance with the protocol.
  2. Male or female aged 18-56 years (inclusive)
  3. (BMI) ≥23 kg/m2 at screening, with stable body weight in the past 4 months
  4. (HbA1c) \< 6.5% and fasting plasma glucose \< 7 mmol/L at screening.
  5. Participants of (including their partners) have no plan to conceive, donate oocytes, or donate sperm from the date of signing the informed consent form until 7 months after the last study drug administration, and must comply with requirements during this period

Exclusion criteria

Exclusion Criteria:

  1. History or presence of liver disease (except fatty liver disease), allergy, cardiovascular, endocrine (except primary obesity), neuropsychiatric, digestive, respiratory, hematological, immune, or genitourinary system major diseases.
  2. History or presence of endocrine diseases that may significantly affect body weight, or obesity caused by medication use, single gene mutation, or genetic obesity syndromes.
  3. Any skin conditions that may interfere with the assessment of injection-site reactions.
  4. Use of any siRNA agent in the prior 12 months
  5. Use of glucagon-like peptide-1 (GLP-1) receptor agonists and other weight-loss medications in the past 6 months.
  6. Use of any prescription or non-prescription drugs (including Chinese herbal medicines, vitamins, minerals, and dietary supplements, etc.) within 2 weeks before dosing or at least 5 elimination half-lives, whichever is longer.
  7. Participants with abnormalities in vital signs, physical examination, laboratory tests, 12-lead , and other auxiliary examinations at screening or baseline, who are considered by the investigator to be ineligible for enrollment.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    SAD:CMS-D008

    5 sequential dose escalation cohorts - participants are randomized either to investigational drug or matching placebo

    Biological: CMS-D008

  • Placebo comparator
    SAD: Placebo

    5 sequential dose escalation cohorts - participants are randomized either to investigational drug or matching placebo

    Drug: Placebo

  • Experimental
    MAD: CMS-D008

    3 sequential dose escalation cohorts - participants are randomized either to investigational drug or matching placebo

    Biological: CMS-D008

  • Placebo comparator
    MAD: Placebo

    3 sequential dose escalation cohorts - participants are randomized either to investigational drug or matching placebo

    Drug: Placebo

  • Experimental
    Expansion study: CMS-D008

    2 sequential dose escalation cohorts - participants are randomized either to investigational drug or matching placebo

    Biological: CMS-D008

  • Placebo comparator
    Expansion study: Placebo

    2 sequential dose escalation cohorts - participants are randomized either to investigational drug or matching placebo

    Drug: Placebo

Interventions

  • BiologicalCMS-D008

    Healthy and overweight or obese participants

  • DrugPlacebo

    Healthy and overweight or obese participants

06

What researchers measure

Primary outcomes

  1. Change from baseline to each visit point in vital signs (temperature, blood pressure, heart rate, respiratory rate)

    Measured using electronic sphygmomanometer/thermometer according to standard procedures, record actual values at each visit point, and assess abnormal values.

    Time frame: through study completion,an average of 0.6 years

  2. Incidence rate of abnormal findings in comprehensive systemic physical examination

    Record abnormal physical examination findings by system (cardiovascular, respiratory, digestive, etc.), summarize the number and incidence rate of abnormalities in each system, and categorize them as related or unrelated to the study drug.

    Time frame: through study completion,an average of 0.6 years

  3. Hematology, biochemistry, and urinalysis laboratory test indicators

    The tests include complete blood count (WBC, RBC, Hb, etc.), blood biochemistry (ALT, AST, Cr, etc.), and urinalysis; changes from baseline were calculated, and the incidence of abnormal values was summarized according to CTCAE 6.0 grading.

    Time frame: through study completion,an average of 0.6 years

  4. 12-lead electrocardiogram QTc interval, heart rate, and incidence of morphological abnormalities

    Collected using standard 12-lead ECG equipment, interpreted by a central laboratory, with the number and incidence rate of QTc interval changes, heart rate abnormalities, and morphological abnormalities (such as premature beats, ST-T changes) summarized.

    Time frame: through study completion,an average of 0.6 years

Secondary outcomes

  1. Maximum plasma drug concentration (Cmax)

    Calculate the maximum observed plasma concentration from the plasma drug concentration-time curve after administration using non-compartmental analysis (NCA), unit: ng/mL

    Time frame: Through 48 hours post-dose

  2. Tmax

    Using non-compartmental analysis (NCA) to calculate the time to reach Cmax after drug administration, unit: h

    Time frame: Through 48 hours post-dose

  3. Area under the curve (AUC0-t)

    Calculate the area under the concentration-time curve from time of administration (0 h) to the last quantifiable concentration time point (t) using non-compartmental analysis (NCA), unit: ng·h/mL

    Time frame: Through 48 hours post-dose

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07518589
Lead sponsor
Shenzhen Kangzhe Biotechnology Co., Ltd.
Responsible party
Sponsor
First posted
Apr 8, 2026
Start date
Apr 2, 2026 (estimated)
Primary completion
Nov 24, 2027 (estimated)
Completion
Dec 10, 2027 (estimated)
Last update
Apr 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion